The Miami-based company develops a range of solutions to diagnose, treat and prevent various conditions, such as molecular diagnostics tests, pharmaceuticals and vaccines.
"Ron has over 40 years of pharmaceutical industry development experience, including over 30 years in regulatory affairs, safety/risk management and quality assurance, which will be of tremendous value as we continue to bring our product candidates to market," CEO Phillip Frost said in a statement.
Previously, Trust held senior regulatory positions at Allergan (AGN), through its acquisition of Durata Therapeutics, and spent over 16 years at Pfizer (PFE) in various regulatory affairs positions.
Most recently, he worked as an independent consultant providing strategic regulatory consulting services to the pharmaceutical industry, Opko noted.
Separately, TheStreet Ratings Team has a "Hold" rating with a score of C- on the stock.
The primary factors that have impacted the rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.
The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income.
As a counter to these strengths, the team also finds that the stock has had a generally disappointing performance in the past year.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: OPK